73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou
New cell-based immunotherapy offered for melanoma

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S
Corrupt endothelial cells found to protect blood cancer cells from chemotherapy

Corrupt endothelial cells found to protect blood cancer cells from chemotherapy

byWeill Cornell Medical CollegePatient-derived-tumor-xenograft (PDX) as models of high-risk T-ALL patients. (A) Schematic representation of the generation and expansion of T-ALL PDX models. PB:

Corrupt endothelial cells found to protect blood cancer cells from chemotherapy

byWeill Cornell Medical CollegePatient-derived-tumor-xenograft (PDX) as models of high-risk T-ALL patients. (A) Schematic representation of the generation and expansion of T-ALL PDX models. PB:
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t
Pharmacotyping of childhood leukemia provides a blueprint for 'true precision medicine'

Pharmacotyping of childhood leukemia provides a blueprint for 'true precision medicine'

bySt. Jude Children's Research HospitalWenjian Yang, Shawn Lee, MBBS, and Jun J. Yang, PhD, recently published a comprehensive study pharmacotyping childhood leukemia. Credit: St. Jude Child

Pharmacotyping of childhood leukemia provides a blueprint for 'true precision medicine'

bySt. Jude Children's Research HospitalWenjian Yang, Shawn Lee, MBBS, and Jun J. Yang, PhD, recently published a comprehensive study pharmacotyping childhood leukemia. Credit: St. Jude Child
Brain tumor research could help future precision medicine

Brain tumor research could help future precision medicine

byUniversity of BristolCredit: CC0 Public DomainNew research on brain tumors could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumors are the

Brain tumor research could help future precision medicine

byUniversity of BristolCredit: CC0 Public DomainNew research on brain tumors could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumors are the
Discovery suggests new way to target mantle cell lymphoma

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti
Discovery New Biomarker for Cancer Stem Cells

Discovery New Biomarker for Cancer Stem Cells

Protein Linked to Tumor Survival and SpreadByLaurie Fickman713-743-8454n the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnor

Discovery New Biomarker for Cancer Stem Cells

Protein Linked to Tumor Survival and SpreadByLaurie Fickman713-743-8454n the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnor
Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo
Immunotherapy for Cancer: What Are My Options?

Immunotherapy for Cancer: What Are My Options?

ByJennifer WelshPublished on September 06, 2023Medically reviewed byDoru Paul, MDImmunotherapy is a relatively new approach to cancer treatment. It improves the body's immu

Immunotherapy for Cancer: What Are My Options?

ByJennifer WelshPublished on September 06, 2023Medically reviewed byDoru Paul, MDImmunotherapy is a relatively new approach to cancer treatment. It improves the body's immu
SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe
New biomarker advances cancer treatments

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n